Shots:
The US FDA has approved label expansion to Evkeeza (evinacumab-dgnb) as an adj. to diet, exercise & other lipid-lowering therapies for the treatment of children (1 to <5yrs.) with homozygous familial hypercholesterolemia (HoFH)
Approval was supported by efficacy & safety results in 6 children with HoFH (incl. PK data from 4) who participated in…
